Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SinoMab Bioscience Ltd. ( (HK:3681) ) just unveiled an update.
SinoMab BioScience Limited announced its audited consolidated annual results for the year ended December 31, 2024, highlighting significant progress in clinical trials and pipeline development. The company’s flagship product, SM03, is in the final review stage for treating rheumatoid arthritis, while SM17 has shown promising results in treating atopic dermatitis. Financially, the company reduced its annual loss by RMB58.0 million, attributed to decreased R&D costs, and raised HKD73.2 million through new share subscriptions. However, the board does not recommend a final dividend for the reporting period.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of novel drugs for treating immunological diseases.
YTD Price Performance: 23.85%
Average Trading Volume: 191,890
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.47B
For detailed information about 3681 stock, go to TipRanks’ Stock Analysis page.